在成熟的中樞神經系統中，有限的神經再生仍舊是現今醫學界的一大挑戰。中樞神經系統受傷之後，再生相關基因不容易被活化，且環境中會出現抑制性分子，降低神經細胞存活率並抑制神經再生。因為中和環境抑制分子對於神經再生的幫助有限，實際上可幫助中樞神經再生的作法為誘導再生相關基因再次活化。組蛋白脫乙醯酶(簡稱HDACs)及組蛋白乙醯轉移酶(簡稱HATs)在組蛋白的修飾上扮演重要的角色，進而調節再生相關基因的表現。P300是一種參與神經系統發育的HAT，但未知其是否能促進大鼠皮質神經細胞的再生。在本篇論文中，我利用從18天大的胎鼠所取出的皮質神經細胞來做實驗，分別加入HDAC的抑制劑Trichostatin A (TSA)及HAT的抑制劑 Anacardic acid (AA)，觀察神經細胞受傷後的再生。初步的結果顯示，TSA能增加組蛋白H3的乙醯化，但沒有促進神經再生的效果。AA則降低組蛋白H3和alpha-tubulin的乙醯化，減少WNT3A的mRNA表現，但不能促進神經再生。另外，在皮質神經細胞中高度表現P300會增加WNT3A的mRNA表現，但無助於神經再生。雖然TSA、AA和高度表現P300會影響到神經細胞內組蛋白的乙醯化或WNT3A的mRNA表現，但並不會促進大鼠皮質神經細胞的再生。

Limited neuronal regeneration is still a challenge for adult central nervous system (CNS). Regeneration-associated genes (RAGs) are difficult to be activated in CNS. There are many inhibitory molecules existing after injury. These molecules decrease neuronal survival and inhibit neuronal regeneration. Since neutralization of the extracellular molecules allows only limited axonal regeneration, one practical approach to promote regeneration of injured adult CNS neurons is to induce re-expression of RAGs. Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are enzymes playing critical roles in histone modification. P300 is a HAT that involves in neuronal differentiation, but whether P300 promotes regeneration of injured rat cortical neurons is unknown. In this thesis, we used E18 rat cortical neurons as a cell model. HDAC inhibitor Trichostatin A (TSA) and HAT inhibitor Anacardic acid (AA) were added respectively to cortical neurons before scraping injury. Results showed that TSA increased the acetylation of histone H3 but has no effect on promoting neurite re-growth of rat cortical neurons. On the other hand, AA decreased the acetylation of histone H3, the acetylation of alpha-tubulin and the mRNA level of WNT3A. Yet, AA did not promote neurite re-growth. In addition, overexpression of P300 increased the mRNA level of WNT3A but did not promote neurite re-growth. Although TSA, AA and overexpression of P300 affected the acetylation of histone or the mRNA level of WNT3A, these treatments did not promote neuronal regeneration of rat cortical neurons.

1. Ando S. Neuronal dysfunction with aging and its amelioration. Proc Jpn Acad Ser B Phys Biol Sci. 2012. 88(6):266-82.
2. Turner RJ, Sharp FR. Implications of MMP9 for blood–brain barrier disruption and hemorrhagic transformation following ischemic stroke. Front Cell Neurosci. 2016. 4;10:56.
3. Alluri H, Wiggins-Dohlvik K, Davis ML, Huang JH, Tharakan B. Blood-brain barrier dysfunction following traumatic brain injury. Metab Brain Dis. 2015. 30(5):1093-104.
4. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010. 28;362(4):329-44.
5. Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. J Neurochem. 2016. 139 Suppl 1:318-324.
6. Ha AD, Fung VS. Huntington's disease. Curr Opin Neurol. 2012. 25(4):491-8.
7. Tiryaki E, Horak HA. ALS and other motor neuron diseases. Continuum (Minneap Minn). 2014. 20(5 Peripheral Nervous System Disorders):1185-207.
8. Eric A. Huebner and Stephen M. Strittmatter. Axon Regeneration in the Peripheral and Central Nervous Systems. Results Probl Cell Differ. 2009. 48: 339–351.
9. Raivich G, Bohatschek M, et al. The AP-1 transcription factor c-Jun is required for efficient axonal regeneration. Neuron. 2004. 8; 43(1):57-67.
10. Seijffers R, Allchorne AJ, Woolf CJ. The transcription factor ATF-3 promotes neurite outgrowth. Mol Cell Neurosci. 2006. 32(1-2):143-54.
11. Bonilla IE, Tanabe K, Strittmatter SM. Small proline-rich repeat protein 1A is expressed by axotomized neurons and promotes axonal outgrowth. J Neurosci. 2002. 15; 22(4):1303-15.
12. Bomze HM, Bulsara KR, et al. Spinal axon regeneration evoked by replacing two growth cone proteins in adult neurons. Nat Neurosci. 2001. 4(1):38-43.
13. Chen MS, Huber AB, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature. 2000 Jan 27; 403(6768):434-9.
14. GrandPré T, Nakamura F, et al. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature. 2000 Jan 27; 403(6768):439-44.
15. McKerracher L, David S, et al. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron. 1994 Oct; 13(4):805-11.
16. Kottis V, Thibault P, et al. Oligodendrocyte-myelin glycoprotein (OMgp) is an inhibitor of neurite outgrowth. J Neurochem. 2002 Sep; 82(6):1566-9.
17. Benson MD, Romero MI, et al. Ephrin-B3 is a myelin-based inhibitor of neurite outgrowth. Proc Natl Acad Sci U S A. 2005 Jul 26; 102(30):10694-9.
18. Moreau-Fauvarque C, Kumanogoh A, et al. The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J Neurosci. 2003 Oct 8; 23(27):9229-39.
19. Atwal JK, Pinkston-Gosse J, et al. PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science. 2008 Nov 7; 322(5903):967-70.
20. Chen B, Hammonds-Odie L, et al. SHP-2 mediates target-regulated axonal termination and NGF-dependent neurite growth in sympathetic neurons. Dev Biol. 2002 Dec 15;252(2):170-87.
21. Geoffroy CG, Zheng B. Myelin-associated inhibitors in axonal growth after CNS injury. Curr Opin Neurobiol. 2014 Aug; 27:31-8. doi: 10.1016.
22. Asher RA, Morgenstern DA, et al. Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. J Neurosci. 2000 Apr 1; 20(7):2427-38.
23. Schmalfeldt M, Bandtlow CE, et al. Brain derived versican V2 is a potent inhibitor of axonal growth. J Cell Sci. 2000 Mar; 113 (Pt 5):807-16.
24. Yamada H, Fredette B, et al. The brain chondroitin sulfate proteoglycan brevican associates with astrocytes ensheathing cerebellar glomeruli and inhibits neurite outgrowth from granule neurons. J Neurosci. 1997 Oct 15; 17(20):7784-95.
25. Inatani M, Honjo M, et al. Inhibitory effects of neurocan and phosphacan on neurite outgrowth from retinal ganglion cells in culture. Invest Ophthalmol Vis Sci. 2001 Jul; 42(8):1930-8.
26. Dou CL, Levine JM. Inhibition of neurite growth by the NG2 chondroitin sulfate proteoglycan. J Neurosci. 1994 Dec; 14(12):7616-28.
27. Rhodes K E, Fawcett J W. Chondroitin sulphate proteoglycans: Preventing plasticity or protecting the CNS? Journal of Anatomy. 2004. 204 (1): 33–48. doi:10.1111.
28. Justin R Siebert, Donna J Osterhout. The inhibitory effects of chondroitin sulfate proteoglycans on oligodendrocytes. J Neurochem. 2011. 119, 176–188.
29. Jones L L, Margolis R U, Tuszynski M H. The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury. 2003. Experimental Neurology. 182 (2): 399–411.
30. Stichel C C, Muller H W. Experimental strategies to promote axonal regeneration after traumatic central nervous system injury. Neurobiol. 1998. 56:119-148
31. Goldberg JL, Klassen MP, et al. Amacrine-signaled loss of intrinsic axon growth ability by retinal ganglion cells. Science. 2002. 7;296(5574):1860-4.
32. Philip J Horner, Fred H Gage. Regenerating the damaged central nervous system. Nature. 2000.407,963-970.
33. Blackmore M, Letourneau PC, et al. Changes within maturing neurons limit axonal regeneration in the developing spinal cord. J Neurobiol. 2006. 66(4):348-60.
34. Yiu G, He Z, et al. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci. 2006 Aug;7(8):617-27.
35. Harel NY, Strittmatter SM, et al. Can regenerating axons recapitulate developmental guidance during recovery from spinal cord injury? Nat Rev Neurosci. 2006 Aug;7(8):603-16.
36. Waddington CH. The epigenotype. Endeavour. 1942; 1:18–20.
37. Wu Ct, Morris JR. Genes, genetics, and epigenetics: a correspondence. Science. 2001 Aug 10; 293(5532):1103-5.
38. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature. 1993. 366 (6453): 362–65.
39. Mattick JS, Amaral PP, et al. RNA regulation of epigenetic processes. BioEssays. 2009. 31 (1): 51–59.
40. Kouzarides T. Chromatin modifications and their function. Cell. 2007. 23; 128(4):693-705.
41. Cathérine Dupont, D Randall Armant, Carol A Brenner. Epigenetics: Definition, Mechanisms and Clinical Perspective. Semin Reprod Med. 2009. 27(5): 351–357.
42. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007 Aug 13;26(37):5310-8.
43. Lee KK, Workman JL. Histone acetyltransferase complexes: one size doesn't fit all. Nature Reviews. Molecular Cell Biology. 2007. 8 (4): 284–95. doi:10.1038
44. Loredana Verdone, et al. Histone acetylation in gene regulation. Briefings in Functional Genomics and Proteomics. 2006. 5 (3):209-221.
45. Wang Z, Zang C, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009. 138: 1019-31.
46. Hsieh J, Nakashima K, et al. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci USA. 2004. 101: 16659-64.
47. Crosio C, Heitz E, et al. Chromatin remodeling and neuronal response: multiple signaling pathways induce specific histone H3 modifications and early gene expression in hippocampal neurons. J Cell Sci. 2003. 116: 4905-14.
48. Roth TL, Sweatt JD. Regulation of chromatin structure in memory formation. Curr Opin Neurobiol. 2009. 19: 336-42.
49. Barrett RM, Wood MA. Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. Learn Mem. 2008. 15: 460
50. Lucia Peixoto, Ted Abel. The Role of Histone Acetylation in Memory Formation and Cognitive Impairments. Neuropsychopharmacology. 2013 Jan; 38(1): 62–76.
51. Kim AH, Puram SV, et al. A centrosomal Cdc20-APC pathway controls dendrite morphogenesis in postmitotic neurons. Cell. 2009 Jan 23; 136(2):322-36.
52. Yongcheol Cho, Roman Sloutsky, et al. Injury-induced HDAC5 nuclear export is essential for axon regeneration. Cell. 2013. 155(4): 894–908
53. Puttagunta R, et al. PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system. Nature Communications. 2014. doi:10.1038 /ncomms4527
54. Vanhaecke T, Papeleu P, Elaut G, Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem. 2004. 11 (12): 1629–43.
55. Drummond DC, Noble CO, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005. 45:495-528.
56. Gaub P, Tedeschi A, et al. HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/P300 and P/CAF-dependent p53 acetylation. Cell Death Differ. 2010. 17(9):1392-408.
57. Tan J, Jiang X, et al. Anacardic acid induces cell apoptosis of prostatic cancer through autophagy by ER stress/DAPK3/Akt signaling pathway. Oncol Rep. 2017 Sep;38(3):1373-1382.
58. Shen Lin,a Kutaiba Nazif, et al. Histone acetylation inhibitors promote axon growth in adult DRG neurons. J Neurosci Res. 2015. 93(8): 1215–1228.
59. Yongcheol Cho, Valeria Cavalli, et al. HDAC signaling in neuronal development and axon regeneration. Curr Opin Neurobiol. 2014. 0: 118–126.
60. Tropberger P, Pott S, et al. Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer. Cell. 2013.152:859-872.
61. Delvecchio M, Gaucher J, et al. Structure of the P300 catalytic core and implications for chromatin targeting and HAT regulation. Nat. Struct. Mol. Biol. 2013. 20:1040-1046.
62. Ogryzko V V, Schiltz R L, et al. The transcriptional coactivators P300 and CBP are histone acetyltransferases. Cell. 1996.87:953-959.
63. Iioka T, Furukawa K, et al. P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1), paired-like homeoprotein, through acetylation of the conserved lysine residue adjacent to the homeodomain. J. Bone Miner. Res. 2003. 18:1419-1429.
64. Qiu Y, Zhao Y, et al. HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol. Cell. 2006. 22:669-679.
65. Han Y, Jin Y H, et al. Acetylation of Sirt2 by P300 attenuates its deacetylase activity. Biochem. Biophys. Res. Commun. 2008. 375:576-580.
66. Braganca J, Eloranta J J, et al. Physical and functional interactions among AP-2 transcription factors, P300/CREB-binding protein, and CITED2. J. Biol. Chem. 2003. 278:16021-16029.
67. Curtis A M, Seo S B, et al. Histone acetyltransferase-dependent chromatin remodeling and the vascular clock. J. Biol. Chem. 2004. 279:7091-7097.
68. Sabari B R, Tang Z, et al. Intracellular crotonyl-CoA stimulates transcription through P300-catalyzed histone crotonylation. Mol. Cell. 2015. 58:203-215.
69. Chen Y, Sprung R, et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol. Cell. Proteomics. 2007. 6:812-819.
70. Marosi K, Kim S W, et al. 3-Hydroxybutyrate regulates energy metabolism and induces BDNF expression in cerebral cortical neurons. J Neurochem. 2016 Dec;139(5):769-781.
71. Sanders YY, Liu H, Zhang X, et al. Histone modifications in senescence-associated resistance to apoptosis by oxidative stress. Redox Biol 2013; 1: 8–16.
72. Shu XZ, Zhang LN, et al. Histone acetyltransferase P300 promotes MRTF-A-mediates transactivation of VE-cadherin gene in human umbilical vein endothelial cells. Gene 2015; 563: 17–23.
73. Li N, Yuan Q, et al. Opposite effects of HDAC5 and P300 on MRTF-A-related neuronal apoptosis during ischemia/reperfusion injury in rats. Cell Death Dis. 2017 Feb 23;8(2):e2624.
74. Gaub P, Joshi Y, et al. The histone acetyltransferase P300 promotes intrinsic axonal regeneration. Brain. 2011 Jul;134(Pt 7):2134-48.
75. Tomioka T, Maruoka H, et al. The histone deacetylase inhibitor trichostatin A induces neurite outgrowth in PC12 cells via the epigenetically regulated expression of the nur77 gene. Neurosci Res. 2014. 88:39-48. doi: 10.1016.
76. Amit K Patel, Kevin K Park, et al. Wnt signaling promotes axonal regeneration following optic nerve injury in the mouse. Neuroscience. 2017 Feb 20; 343: 372–383.
77. Hemshekhar M, et al. Emerging roles of anacardic acid and its derivatives: a pharmacological overview. Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):122-32.
78. Sun Y, et al. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett. 2006;580:4353–6.
79. Schneider A,et al. Acetyltransferases (HATs) as targets for neurological therapeutics. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2013; 10(4):568–588.
80. Valor LM, et al. Lysine acetyltransferases CBP and P300 as therapeutic targets in cognitive and neurodegenerative disorders. Current pharmaceutical design. 2013; 19(28):5051–5064.
81. Creppe C, Buschbeck M. Elongator: an ancestral complex driving transcription and migration through protein acetylation. Journal of biomedicine & biotechnology. 2011; 2011:924898.
82. Akella JS, et al. MEC-17 is an alpha-tubulin acetyltransferase. Nature. 2010; 467(7312):218–222.
83. Kalebic N, et al. alphaTAT1 is the major alpha-tubulin acetyltransferase in mice. Nature communications. 2013; 4:1962.
84. Song Y, Brady ST. Post-translational modifications of tubulin: pathways to functional diversity of microtubules. Trends Cell Biol. 2015 Mar;25(3):125-36.